Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a ...

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...